Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GHoST Protocol for Home-Based Sequential Therapy in Glioma
NCT07074756Recruiting
- Sponsor
- Mayo Clinic
- Start
- Sep 2025
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Randomised, open-label trial of propranolol and imipramine in glioblastoma (GBM) (3 arms), sponsored by Mayo Clinic. Primary endpoints: Feasibility - completion of study visits at 6 months and 4-month progression-free survival rate. Started Sep 2025; status: recruiting.
02
Drugs
propranololimipramine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07074756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07074756.